Cipla Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 13, 2025, 9:37 pm

Market Cap	1,21,630 Cr.
Current Price	1,505
High / Low	1,702/1,310
Stock P/E	23.1
Book Value	386
Dividend Yield	0.86 %
ROCE	23.3 %
ROE	18.2 %
Face Value	2.00
PEG Ratio	1.36

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Cipla Ltd

Competitors of Cipla Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	142 Cr.	101	247/84.3	27.6	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.27 Cr.	2.76	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	41.6 Cr.	56.0	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	32.1 Cr.	21.9	29.1/13.1	31.4	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,999.77 Cr	1,191.58		92.43	194.72	0.30%	16.67%	15.20%	6.18

All Competitor Stocks of Cipla Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	5,260	5,375	5,829	5,810	5,739	6,329	6,678	6,604	6,163	6,694	7,051	7,073	6,730
Expenses	4,511	4,232	4,526	4,403	4,566	4,835	4,944	4,856	4,847	4,978	5,165	5,084	5,192
Operating Profit	750	1,143	1,302	1,408	1,174	1,494	1,734	1,748	1,316	1,716	1,886	1,989	1,538
OPM %	14%	21%	22%	24%	20%	24%	26%	26%	21%	26%	27%	28%	23%
Other Income	7	103	123	114	-48	136	176	-10	249	160	191	222	289
Interest	18	18	26	32	34	16	26	30	18	18	15	15	14
Depreciation	290	254	299	272	346	239	290	233	288	247	272	280	309
Profit before tax	448	975	1,100	1,218	745	1,375	1,594	1,474	1,259	1,611	1,789	1,916	1,504
Tax %	16%	28%	28%	34%	30%	28%	28%	28%	26%	27%	27%	17%	19%
Net Profit	371	706	797	808	522	998	1,155	1,068	932	1,175	1,305	1,575	1,214
EPS in Rs	4.49	8.51	9.78	9.92	6.51	12.33	14.01	13.08	11.63	14.58	16.13	19.45	15.13

Last Updated: May 31, 2025, 9:31 am

Below is a detailed analysis of the quarterly data for Cipla Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 6,730.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7,073.00 Cr. (Dec 2024) to 6,730.00 Cr., marking a decrease of 343.00 Cr..
For Expenses, as of Mar 2025, the value is 5,192.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5,084.00 Cr. (Dec 2024) to 5,192.00 Cr., marking an increase of 108.00 Cr..
For Operating Profit, as of Mar 2025, the value is 1,538.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,989.00 Cr. (Dec 2024) to 1,538.00 Cr., marking a decrease of 451.00 Cr..
For OPM %, as of Mar 2025, the value is 23.00%. The value appears to be declining and may need further review. It has decreased from 28.00% (Dec 2024) to 23.00%, marking a decrease of 5.00%.
For Other Income, as of Mar 2025, the value is 289.00 Cr.. The value appears strong and on an upward trend. It has increased from 222.00 Cr. (Dec 2024) to 289.00 Cr., marking an increase of 67.00 Cr..
For Interest, as of Mar 2025, the value is 14.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 15.00 Cr. (Dec 2024) to 14.00 Cr., marking a decrease of 1.00 Cr..
For Depreciation, as of Mar 2025, the value is 309.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 280.00 Cr. (Dec 2024) to 309.00 Cr., marking an increase of 29.00 Cr..
For Profit before tax, as of Mar 2025, the value is 1,504.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,916.00 Cr. (Dec 2024) to 1,504.00 Cr., marking a decrease of 412.00 Cr..
For Tax %, as of Mar 2025, the value is 19.00%. The value appears to be increasing, which may not be favorable. It has increased from 17.00% (Dec 2024) to 19.00%, marking an increase of 2.00%.
For Net Profit, as of Mar 2025, the value is 1,214.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,575.00 Cr. (Dec 2024) to 1,214.00 Cr., marking a decrease of 361.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 15.13. The value appears to be declining and may need further review. It has decreased from 19.45 (Dec 2024) to 15.13, marking a decrease of 4.32.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: May 15, 2025, 6:58 am

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	10,173	11,345	13,790	14,394	15,156	16,362	17,132	19,160	21,763	22,753	25,774	27,548
Expenses	8,026	9,183	11,310	11,898	12,329	13,265	13,926	14,907	17,211	17,726	19,483	20,420
Operating Profit	2,147	2,163	2,480	2,496	2,826	3,097	3,206	4,252	4,553	5,027	6,291	7,128
OPM %	21%	19%	18%	17%	19%	19%	19%	22%	21%	22%	24%	26%
Other Income	251	164	208	208	280	477	344	266	99	293	552	862
Interest	146	168	207	159	114	168	197	161	106	110	90	62
Depreciation	373	505	754	1,323	1,323	1,326	1,175	1,068	1,052	1,172	1,051	1,107
Profit before tax	1,880	1,654	1,727	1,222	1,669	2,079	2,178	3,290	3,493	4,038	5,702	6,821
Tax %	25%	24%	19%	15%	15%	27%	29%	27%	27%	30%	27%	22%
Net Profit	1,404	1,229	1,383	1,035	1,417	1,492	1,500	2,389	2,547	2,833	4,154	5,269
EPS in Rs	17.29	14.71	16.93	12.51	17.52	18.96	19.18	29.82	31.19	34.71	51.05	65.28
Dividend Payout %	12%	14%	12%	16%	17%	16%	21%	17%	16%	24%	25%	25%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	-12.46%	12.53%	-25.16%	36.91%	5.29%	0.54%	59.27%	6.61%	11.23%	46.63%	26.84%
Change in YoY Net Profit Growth (%)	0.00%	24.99%	-37.69%	62.07%	-31.62%	-4.76%	58.73%	-52.65%	4.62%	35.40%	-19.79%

Cipla Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	9%
5 Years:	10%
3 Years:	8%
TTM:	7%

Compounded Profit Growth
10 Years:	16%
5 Years:	30%
3 Years:	27%
TTM:	25%

Stock Price CAGR
10 Years:	10%
5 Years:	18%
3 Years:	16%
1 Year:	-3%

Return on Equity
10 Years:	13%
5 Years:	15%
3 Years:	16%
Last Year:	18%

Last Updated: Unknown

Balance Sheet

Last Updated: June 12, 2025, 3:40 pm

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	161	161	161	161	161	161	161	161	161	161	161	162
Reserves	9,890	10,641	11,356	12,383	14,068	14,851	15,602	18,165	20,680	23,246	26,545	31,032
Borrowings	1,248	1,703	5,202	4,113	4,098	4,316	2,816	2,014	1,056	803	559	438
Other Liabilities	2,102	3,166	4,331	4,213	4,346	4,433	4,843	4,514	4,960	5,089	5,267	5,755
Total Liabilities	13,400	15,670	21,049	20,869	22,673	23,762	23,423	24,855	26,857	29,300	32,533	37,387
Fixed Assets	6,496	6,830	9,368	9,492	9,950	9,608	9,683	9,516	9,683	9,160	9,607	10,360
CWIP	442	581	2,061	1,683	981	676	825	969	766	1,093	1,153	1,213
Investments	709	640	759	973	1,259	2,554	1,471	2,710	2,551	3,662	5,449	7,933
Other Assets	5,753	7,620	8,862	8,721	10,483	10,923	11,444	11,661	13,857	15,384	16,323	17,882
Total Assets	13,400	15,670	21,049	20,869	22,673	23,762	23,423	24,855	26,857	29,300	32,533	37,387

Below is a detailed analysis of the balance sheet data for Cipla Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 162.00 Cr.. The value appears strong and on an upward trend. It has increased from 161.00 Cr. (Mar 2024) to 162.00 Cr., marking an increase of 1.00 Cr..
For Reserves, as of Mar 2025, the value is 31,032.00 Cr.. The value appears strong and on an upward trend. It has increased from 26,545.00 Cr. (Mar 2024) to 31,032.00 Cr., marking an increase of 4,487.00 Cr..
For Borrowings, as of Mar 2025, the value is 438.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 559.00 Cr. (Mar 2024) to 438.00 Cr., marking a decrease of 121.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 5,755.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 5,267.00 Cr. (Mar 2024) to 5,755.00 Cr., marking an increase of 488.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 37,387.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32,533.00 Cr. (Mar 2024) to 37,387.00 Cr., marking an increase of 4,854.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 10,360.00 Cr.. The value appears strong and on an upward trend. It has increased from 9,607.00 Cr. (Mar 2024) to 10,360.00 Cr., marking an increase of 753.00 Cr..
For CWIP, as of Mar 2025, the value is 1,213.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,153.00 Cr. (Mar 2024) to 1,213.00 Cr., marking an increase of 60.00 Cr..
For Investments, as of Mar 2025, the value is 7,933.00 Cr.. The value appears strong and on an upward trend. It has increased from 5,449.00 Cr. (Mar 2024) to 7,933.00 Cr., marking an increase of 2,484.00 Cr..
For Other Assets, as of Mar 2025, the value is 17,882.00 Cr.. The value appears strong and on an upward trend. It has increased from 16,323.00 Cr. (Mar 2024) to 17,882.00 Cr., marking an increase of 1,559.00 Cr..
For Total Assets, as of Mar 2025, the value is 37,387.00 Cr.. The value appears strong and on an upward trend. It has increased from 32,533.00 Cr. (Mar 2024) to 37,387.00 Cr., marking an increase of 4,854.00 Cr..

Notably, the Reserves (31,032.00 Cr.) exceed the Borrowings (438.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	1.00	1.00	-3.00	-2.00	-2.00	-1.00	1.00	2.00	3.00	-798.00	-553.00	-431.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	74	59	64	62	65	75	93	83	66	57	65	68
Inventory Days	295	273	329	273	239	271	250	267	232	230	228	217
Days Payable	102	92	126	106	108	142	123	139	103	108	112	102
Cash Conversion Cycle	266	239	267	230	196	204	220	211	195	180	181	182
Working Capital Days	142	126	133	121	111	129	143	122	106	103	122	125
ROCE %	24%	19%	15%	13%	7%	9%	11%	12%	17%	17%	18%	23%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	33.63%	33.61%	33.61%	33.61%	33.55%	33.46%	33.46%	33.46%	33.46%	30.91%	30.93%	29.19%
FIIs	26.65%	27.65%	27.69%	28.39%	27.42%	25.49%	25.74%	25.73%	25.82%	27.82%	28.80%	26.65%
DIIs	21.99%	21.33%	21.47%	20.87%	21.83%	24.05%	23.90%	24.05%	24.15%	24.66%	23.95%	27.49%
Government	0.00%	0.00%	0.21%	0.21%	0.21%	0.21%	0.21%	0.21%	0.21%	0.21%	0.21%	0.23%
Public	17.73%	17.40%	17.00%	16.91%	16.99%	16.76%	16.68%	16.53%	16.36%	16.40%	16.11%	16.43%
No. of Shareholders	4,18,584	4,18,910	3,88,864	4,04,182	4,75,293	4,66,515	4,26,863	4,25,731	4,36,154	4,63,569	4,70,234	5,25,114

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
HDFC Flexi Cap Fund - Regular Plan	19,200,000	4.82	2965.06	19,200,000	2025-04-22 17:25:38	0%
HDFC ELSS Tax Saver Fund	5,400,000	5.17	833.92	5,400,000	2025-04-22 17:25:38	0%
HDFC Focused 30 Fund - Regular Plan	4,000,000	4.48	617.72	4,000,000	2025-04-22 17:25:38	0%
SBI Contra Fund	3,836,985	1.57	592.55	3,836,985	2025-04-22 17:25:38	0%
SBI Long Term Equity Fund	3,403,528	1.91	525.61	3,403,528	2025-04-22 17:25:38	0%
HDFC Top 100 Fund - Regular Plan	2,266,282	0.94	349.98	2,266,282	2025-04-22 12:29:18	0%
Kotak Equity Arbitrage Fund - Regular Plan	2,083,250	0.62	321.72	2,083,250	2025-04-22 17:25:38	0%
HDFC Balanced Advantage Fund - Regular Plan	1,733,243	0.28	267.66	1,733,243	2025-04-22 17:25:38	0%
Kotak Equity Opportunities Fund - Regular Plan	1,500,000	0.92	231.65	1,500,000	2025-04-22 17:25:38	0%
DSP Healthcare Fund	1,386,069	7.77	214.05	1,386,069	2025-04-22 17:25:38	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	2.00	2.00	2.00	2.00	2.00
Basic EPS (Rs.)	51.05	34.72	31.20	29.82	19.19
Diluted EPS (Rs.)	51.01	34.69	31.17	29.79	19.16
Cash EPS (Rs.)	64.49	49.65	44.76	43.02	33.76
Book Value[Excl.RevalReserv]/Share (Rs.)	331.98	293.79	261.74	230.46	199.16
Book Value[Incl.RevalReserv]/Share (Rs.)	331.98	293.79	261.74	230.46	199.16
Revenue From Operations / Share (Rs.)	319.24	281.89	269.75	237.58	212.49
PBDIT / Share (Rs.)	87.17	68.17	59.91	56.03	44.03
PBIT / Share (Rs.)	74.15	53.65	46.87	42.79	29.46
PBT / Share (Rs.)	70.62	50.03	43.30	40.80	27.02
Net Profit / Share (Rs.)	51.47	35.13	31.72	29.78	19.19
NP After MI And SOA / Share (Rs.)	51.05	34.71	31.19	29.82	19.18
PBDIT Margin (%)	27.30	24.18	22.21	23.58	20.72
PBIT Margin (%)	23.22	19.03	17.37	18.01	13.86
PBT Margin (%)	22.12	17.74	16.05	17.17	12.71
Net Profit Margin (%)	16.12	12.46	11.76	12.53	9.02
NP After MI And SOA Margin (%)	15.99	12.31	11.56	12.55	9.02
Return on Networth / Equity (%)	15.43	11.96	12.07	13.12	9.81
Return on Capital Employeed (%)	21.79	17.78	17.04	16.78	12.32
Return On Assets (%)	12.59	9.50	9.28	9.56	6.53
Long Term Debt / Equity (X)	0.00	0.00	0.01	0.06	0.15
Total Debt / Equity (X)	0.01	0.02	0.03	0.08	0.17
Asset Turnover Ratio (%)	0.82	0.57	0.51	0.59	0.57
Current Ratio (X)	3.71	3.38	3.00	2.88	2.66
Quick Ratio (X)	2.71	2.37	1.91	1.86	1.67
Inventory Turnover Ratio (X)	1.00	0.81	0.70	0.87	0.85
Dividend Payout Ratio (NP) (%)	16.64	0.00	0.00	0.00	36.48
Dividend Payout Ratio (CP) (%)	13.26	0.00	0.00	0.00	20.73
Earning Retention Ratio (%)	83.36	0.00	0.00	0.00	63.52
Cash Earning Retention Ratio (%)	86.74	0.00	0.00	0.00	79.27
Interest Coverage Ratio (X)	78.30	50.23	45.45	28.12	17.99
Interest Coverage Ratio (Post Tax) (X)	49.40	28.55	26.78	15.94	8.84
Enterprise Value (Cr.)	120138.52	71957.46	81343.93	66141.15	36211.18
EV / Net Operating Revenue (X)	4.66	3.16	3.74	3.45	2.11
EV / EBITDA (X)	17.07	13.08	16.83	14.64	10.20
MarketCap / Net Operating Revenue (X)	4.68	3.19	3.78	3.43	1.99
Retention Ratios (%)	83.35	0.00	0.00	0.00	63.51
Price / BV (X)	4.52	3.11	3.94	3.59	2.16
Price / Net Operating Revenue (X)	4.68	3.19	3.78	3.43	1.99
EarningsYield	0.03	0.03	0.03	0.03	0.04

After reviewing the key financial ratios for Cipla Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 2.00.
For Basic EPS (Rs.), as of Mar 24, the value is 51.05. This value is within the healthy range. It has increased from 34.72 (Mar 23) to 51.05, marking an increase of 16.33.
For Diluted EPS (Rs.), as of Mar 24, the value is 51.01. This value is within the healthy range. It has increased from 34.69 (Mar 23) to 51.01, marking an increase of 16.32.
For Cash EPS (Rs.), as of Mar 24, the value is 64.49. This value is within the healthy range. It has increased from 49.65 (Mar 23) to 64.49, marking an increase of 14.84.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 331.98. It has increased from 293.79 (Mar 23) to 331.98, marking an increase of 38.19.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 331.98. It has increased from 293.79 (Mar 23) to 331.98, marking an increase of 38.19.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 319.24. It has increased from 281.89 (Mar 23) to 319.24, marking an increase of 37.35.
For PBDIT / Share (Rs.), as of Mar 24, the value is 87.17. This value is within the healthy range. It has increased from 68.17 (Mar 23) to 87.17, marking an increase of 19.00.
For PBIT / Share (Rs.), as of Mar 24, the value is 74.15. This value is within the healthy range. It has increased from 53.65 (Mar 23) to 74.15, marking an increase of 20.50.
For PBT / Share (Rs.), as of Mar 24, the value is 70.62. This value is within the healthy range. It has increased from 50.03 (Mar 23) to 70.62, marking an increase of 20.59.
For Net Profit / Share (Rs.), as of Mar 24, the value is 51.47. This value is within the healthy range. It has increased from 35.13 (Mar 23) to 51.47, marking an increase of 16.34.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 51.05. This value is within the healthy range. It has increased from 34.71 (Mar 23) to 51.05, marking an increase of 16.34.
For PBDIT Margin (%), as of Mar 24, the value is 27.30. This value is within the healthy range. It has increased from 24.18 (Mar 23) to 27.30, marking an increase of 3.12.
For PBIT Margin (%), as of Mar 24, the value is 23.22. This value exceeds the healthy maximum of 20. It has increased from 19.03 (Mar 23) to 23.22, marking an increase of 4.19.
For PBT Margin (%), as of Mar 24, the value is 22.12. This value is within the healthy range. It has increased from 17.74 (Mar 23) to 22.12, marking an increase of 4.38.
For Net Profit Margin (%), as of Mar 24, the value is 16.12. This value exceeds the healthy maximum of 10. It has increased from 12.46 (Mar 23) to 16.12, marking an increase of 3.66.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 15.99. This value is within the healthy range. It has increased from 12.31 (Mar 23) to 15.99, marking an increase of 3.68.
For Return on Networth / Equity (%), as of Mar 24, the value is 15.43. This value is within the healthy range. It has increased from 11.96 (Mar 23) to 15.43, marking an increase of 3.47.
For Return on Capital Employeed (%), as of Mar 24, the value is 21.79. This value is within the healthy range. It has increased from 17.78 (Mar 23) to 21.79, marking an increase of 4.01.
For Return On Assets (%), as of Mar 24, the value is 12.59. This value is within the healthy range. It has increased from 9.50 (Mar 23) to 12.59, marking an increase of 3.09.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Total Debt / Equity (X), as of Mar 24, the value is 0.01. This value is within the healthy range. It has decreased from 0.02 (Mar 23) to 0.01, marking a decrease of 0.01.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.82. It has increased from 0.57 (Mar 23) to 0.82, marking an increase of 0.25.
For Current Ratio (X), as of Mar 24, the value is 3.71. This value exceeds the healthy maximum of 3. It has increased from 3.38 (Mar 23) to 3.71, marking an increase of 0.33.
For Quick Ratio (X), as of Mar 24, the value is 2.71. This value exceeds the healthy maximum of 2. It has increased from 2.37 (Mar 23) to 2.71, marking an increase of 0.34.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.00. This value is below the healthy minimum of 4. It has increased from 0.81 (Mar 23) to 1.00, marking an increase of 0.19.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 16.64. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 23) to 16.64, marking an increase of 16.64.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 13.26. This value is below the healthy minimum of 20. It has increased from 0.00 (Mar 23) to 13.26, marking an increase of 13.26.
For Earning Retention Ratio (%), as of Mar 24, the value is 83.36. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 83.36, marking an increase of 83.36.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 86.74. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 86.74, marking an increase of 86.74.
For Interest Coverage Ratio (X), as of Mar 24, the value is 78.30. This value is within the healthy range. It has increased from 50.23 (Mar 23) to 78.30, marking an increase of 28.07.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 49.40. This value is within the healthy range. It has increased from 28.55 (Mar 23) to 49.40, marking an increase of 20.85.
For Enterprise Value (Cr.), as of Mar 24, the value is 120,138.52. It has increased from 71,957.46 (Mar 23) to 120,138.52, marking an increase of 48,181.06.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 4.66. This value exceeds the healthy maximum of 3. It has increased from 3.16 (Mar 23) to 4.66, marking an increase of 1.50.
For EV / EBITDA (X), as of Mar 24, the value is 17.07. This value exceeds the healthy maximum of 15. It has increased from 13.08 (Mar 23) to 17.07, marking an increase of 3.99.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 4.68. This value exceeds the healthy maximum of 3. It has increased from 3.19 (Mar 23) to 4.68, marking an increase of 1.49.
For Retention Ratios (%), as of Mar 24, the value is 83.35. This value exceeds the healthy maximum of 70. It has increased from 0.00 (Mar 23) to 83.35, marking an increase of 83.35.
For Price / BV (X), as of Mar 24, the value is 4.52. This value exceeds the healthy maximum of 3. It has increased from 3.11 (Mar 23) to 4.52, marking an increase of 1.41.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 4.68. This value exceeds the healthy maximum of 3. It has increased from 3.19 (Mar 23) to 4.68, marking an increase of 1.49.
For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.03.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Cipla Ltd as of June 13, 2025 is: 1,309.42

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 13, 2025, Cipla Ltd is Overvalued by 13.00% compared to the current share price 1,505.00

Intrinsic Value of Cipla Ltd as of June 13, 2025 is: 1,531.56

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 13, 2025, Cipla Ltd is Undervalued by 1.76% compared to the current share price 1,505.00

Last 5 Year EPS CAGR: 16.96%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 15.42%, which is a positive sign. The company has higher reserves (17,371.58 cr) compared to borrowings (2,363.83 cr), indicating strong financial stability. The company has shown consistent growth in sales (17.50 cr) and profit (2.50 cr) over the years.	The stock has a high average Working Capital Days of 123.58, which may not be favorable. The stock has a high average Cash Conversion Cycle of 214.25, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Cipla Ltd:
1. Net Profit Margin: 16.12%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 21.79% (Industry Average ROCE: 16.67%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 15.43% (Industry Average ROE: 15.2%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 49.4
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 2.71
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 23.1 (Industry average Stock P/E: 92.43)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.01
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 19044.85 Cr. and Equity Capital is Rs. 161.52 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	Cipla House, Peninsula Business Park, Mumbai Maharashtra 400013	cosecretary@cipla.com http://www.cipla.com

Management
Name	Position Held
Dr. Y K Hamied	Chairman
Mr. M K Hamied	Vice Chairman
Mr. Umang Vohra	Managing Director & Global CEO
Ms. Samina Hamied	Non Exe.Non Ind.Director
Mr. S Radhakrishnan	Non Exe.Non Ind.Director
Mr. Ashok Sinha	Independent Director
Mr. P R Ramesh	Independent Director
Mr. Robert Stewart	Independent Director
Dr. Mandar Vaidya	Independent Director
Mr. Adil Zainulbhai	Independent Director
Ms. Punita Lal	Independent Director
Dr. Balram Bhargava	Independent Director

FAQ

What is the intrinsic value of Cipla Ltd?

Cipla Ltd's intrinsic value (as of 13 June 2025) is ₹1309.42 — 13.00% lower the current market price of 1,505.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,21,630 Cr. market cap, FY2025-2026 high/low of ₹1,702/1,310, reserves of 31,032 Cr, and liabilities of 37,387 Cr.

What is the Market Cap of Cipla Ltd?

The Market Cap of Cipla Ltd is 1,21,630 Cr..

What is the current Stock Price of Cipla Ltd as on 13 June 2025?

The current stock price of Cipla Ltd as on 13 June 2025 is 1,505.

What is the High / Low of Cipla Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Cipla Ltd stocks is ₹1,702/1,310.

What is the Stock P/E of Cipla Ltd?

The Stock P/E of Cipla Ltd is 23.1.

What is the Book Value of Cipla Ltd?

The Book Value of Cipla Ltd is 386.

What is the Dividend Yield of Cipla Ltd?

The Dividend Yield of Cipla Ltd is 0.86 %.

What is the ROCE of Cipla Ltd?

The ROCE of Cipla Ltd is 23.3 %.

What is the ROE of Cipla Ltd?

The ROE of Cipla Ltd is 18.2 %.

What is the Face Value of Cipla Ltd?

The Face Value of Cipla Ltd is 2.00.